All Stories

  1. Structural characterization ofPorphyromonas gingivalisenoyl-ACP reductase II (FabK)

    Article • Acta Crystallographica Section F Structural Biology Communications, January 2018, International Union of Crystallography

    Kirk Hevener, Dr. Kirk E. Hevener

  2. SmTopI Purification

    Article • Protein Expression and Purification, August 2016, Elsevier

    Dr. Kirk E. Hevener

  3. Recent advances in the rational design and optimization of antibacterial agents

    Article • MedChemComm, January 2016, Royal Society of Chemistry

    Dr. Kirk E. Hevener

  4. Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies ofF. tularensisenoyl-ACP reductase (FabI)

    Article • Journal of Computational Chemistry, July 2015, Wiley

    Dr. Kirk E. Hevener

  5. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI)

    Article • Bioorganic & Medicinal Chemistry Letters, March 2015, Elsevier

    Dr. Kirk E. Hevener

  6. High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes

    Article • PLoS ONE, October 2013, PLOS

    Dr. Kirk E. Hevener

  7. Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis

    Article • Journal of Medicinal Chemistry, September 2013, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  8. Synergistic Inhibitor Binding to the Papain-Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications

    Article • ChemMedChem, June 2013, Wiley

    Dr. Kirk E. Hevener

  9. Fragment-Based Drug Discovery Using a Multidomain, Parallel MD-MM/PBSA Screening Protocol

    Article • Journal of Chemical Information and Computer Sciences, March 2013, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  10. High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion

    Article • Protein Expression and Purification, March 2013, Elsevier

    Dr. Kirk E. Hevener

  11. Special Challenges to the Rational Design of Antibacterial Agents

    Article • January 2013, Elsevier

    Dr. Kirk E. Hevener

  12. Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis

    Article • Protein Expression and Purification, September 2012, Elsevier

    Dr. Kirk E. Hevener

  13. Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors

    Article • Journal of Medicinal Chemistry, June 2012, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  14. Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching

    Article • Journal of Medicinal Chemistry, January 2012, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  15. Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase

    Article • Journal of Medicinal Chemistry, January 2010, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  16. Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase

    Article • Journal of Chemical Information and Computer Sciences, February 2009, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  17. A statistical framework to evaluate virtual screening

    Article • BMC Bioinformatics, January 2009, Springer Science + Business Media

    Dr. Kirk E. Hevener

  18. Quantitative structure–activity relationship studies on nitrofuranyl anti-tubercular agents

    Article • Bioorganic & Medicinal Chemistry, September 2008, Elsevier

    Dr. Kirk E. Hevener

  19. Structure–activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors

    Article • Bioorganic & Medicinal Chemistry, February 2006, Elsevier

    Dr. Kirk E. Hevener

  20. Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents

    Article • Journal of Medicinal Chemistry, October 2004, American Chemical Society (ACS)

    Dr. Kirk E. Hevener

  21. The Structure of the Pantothenate Kinase{middle dot}ADP{middle dot}Pantothenate Ternary Complex Reveals the Relationship between the Binding Sites for Substrate, Allosteric Regulator, and Antimetabolites

    Article • Journal of Biological Chemistry, May 2004, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Kirk E. Hevener